Neuron23 and Qiagen partner on NGS companion diagnostic for LRRK2 inhibitor

The early-stage biotech Neuron23 and Qiagen (NYSE:QGEN) will work together to develop the first next-generation sequencing (NGS) companion diagnostic for Neuron23’s leucine-rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease NEU-723. 

In the collaboration, Qiagen will focus on developing and validating a clinical trial assay to detect biomarkers that predict the responsiveness of Parkinson’s disease patients to an LRRK2 inhibitor. 

The companion diagnostic is the first to be developed for Parkinson’s, according to Neuron23 CEO Nancy Stagliano. “Qiagen’s blood-based test will help to identify patients with Parkinson’s disease who are likely to respond to Neuron23’s LRRK2 inhibitor,” Stagliano said in a news release. “The development of a companion diagnostic identifying this sub-population of Parkinson’s disease patients will de-risk the clinical development of Neuron23’s LRRK2 inhibitor and help identify individuals who may benefit from this disease-…

Read more
  • 0

Neuron23 names Kathy Dong to its board

The early-stage biotechnology firm Neuron23 has recruited the chief operating officer of Star Therapeutics, Kathy Dong, to join its board of directors.

Founded in 2018, Neuron23 (South San Francisco) specializes in the discovery and development of drugs for neurodegenerative and immunological diseases, drawing insights from data science.

Star Therapeutics (South San Francisco) focuses on the discovery and development of therapeutics that can treat multiple rare diseases.

Before joining Star Therapeutics, Dong worked for a number of pharma companies, including Gilead Sciences, True North Therapeutics and Sanofi.

Kathy Dong

At Gilead, she oversaw the commercial launch of hepatitis B and C therapies such as SOVALDI (sofosbuvir) and HARVONI (ledipasvir/sofosbuvir).

“I am thrilled to welcome someone of Kathy’s caliber and expertise to Neuron23’s board of directors,” said Nancy Staglian…

Read more
  • 0